

Adjunct minocycline no benefit for treatmentresistant depression

September 15 2022



For patients with treatment-resistant depression (TRD), minocycline as



add-on to antidepressant treatment as usual does not reduce depressive symptoms, according to a study published online Sept. 14 in *JAMA Network Open*.

Julian Hellmann-Regen, M.D., from Charité—Universitätsmedizin Berlin, and colleagues conducted a trial involving <u>patients</u> with TRD who were randomly assigned to receive adjunct minocycline or placebo in a 1:1 ratio for six weeks (84 and 89, respectively). The participants (mean age, 46.1 years), recruited from January 2016 to August 2020 at nine university hospitals, had failed to adequately respond to an initial antidepressant standard medication as per the Massachusetts General Hospital Antidepressant Treatment History Questionnaire.

The researchers found that compared with placebo, minocycline treatment did not alter the course of depression as assessed by a Montgomery Åsberg Depression Rating Scale score over six weeks of treatment (1.46; 95 percent confidence interval, -1.04 to 3.96; P = 0.25). Minocycline treatment also had no significant effect on secondary outcomes, including response, remission, and other clinical rating scales.

"Our results from this large randomized clinical trial of a pleiotropic antiinflammatory drug in this difficult-to-treat patient population are of great clinical importance, robustly demonstrating that minocycline addon treatment does not outperform placebo," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

More information: Julian Hellmann-Regen et al, Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression, *JAMA Network Open* (2022). DOI: 10.1001/jamanetworkopen.2022.30367



Copyright © 2022 HealthDay. All rights reserved.

Citation: Adjunct minocycline no benefit for treatment-resistant depression (2022, September 15) retrieved 24 April 2024 from https://medicalxpress.com/news/2022-09-adjunct-minocycline-benefit-treatment-resistant-depression.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.